SEC Form 4/A · accession 0001123292-17-000717
Recro Pharma, Inc. · REPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
SCP Vitalife Partners II LP
10% Owner
Period of report
Feb 14, 2017
Accepted (ET)
Mar 20, 2017 · 3:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001588972
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Feb 14, 2017 | S | 2,293 | $7.9559 | D | 2,312,594 | D | |
| Common StockF3 | Feb 15, 2017 | S | 6,479 | $7.88 | D | 2,306,115 | D | |
| Common StockF4,F5 | Feb 16, 2017 | S | 3,293 | $7.8572 | D | 2,302,822 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.90 to $8.01, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.78 to $7.99, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4.
- F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.78 to $7.93, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4.
- F5This amendment corrects a previous clerical error to the "Amount of Securities Beneficially Owned Following Reported Transaction" contained in the Form 4 filed on February 17, 2017.